Illustrative certificateNS-2026-06042

Nordicstar Analytical Sciences

CJC-1295 with DAC 5 MG

99.665%HPLC purity

Lot: GLZ-26-CJCDAC-1041
Measured content: 5.02 mg
Mass-spec identity: Confirmed
Endotoxin: <1.0 EU/mg
Tested: 16 Sep 2026

View Lab Report

Repair & Recovery

CJC-1295 with DAC

Q: What is the difference between CJC-1295 DAC and CJC-1295 No DAC?

CJC-1295 with DAC contains a Drug Affinity Complex modification designed to extend peptide exposure through albumin binding. No-DAC material does not contain this modification and represents a different research format.

Q: What does "DAC" mean?

DAC stands for Drug Affinity Complex. It is a reactive maleimide-containing linker attached to the peptide designed to form a covalent bond with serum albumin, the most abundant protein in blood, to protect the peptide from rapid clearance.

Q: Is this product the same as Modified GRF (1-29)?

No. Modified GRF (1-29) is commonly referred to as CJC-1295 No DAC. The DAC-containing molecule is structurally distinct because of the albumin-binding linker.

Albumin association & GHRH-axis research

$51.00USD / vialView COA

A pair saves 10%. A set of three saves 15%.

For laboratory research use only.
Not for human consumption or clinical use.

Compound details

Compound: CJC-1295 with DAC
CAS number: 863288-34-0
Molecular formula: C165H269N47O46
Molecular weight: 3647.18 g/mol
Form: Lyophilized

Quality & documentation

The records shown here are illustrative. Request laboratory-issued documentation for your lot before ordering.

Lot: GLZ-26-CJCDAC-1041
HPLC purity: 99.665%
Measured content: 5.02 mg
Tested: 16 Sep 2026
Report: NS-2026-06042

View the 5 MG certificate

Our quality approach

Shipping & handling

Priority, tracked shipping within the United States, free on orders of $200 or more after savings. Add Priority dispatch at checkout to have your order packed first; Private Clients receive it on every order. Follow the product documentation for laboratory handling requirements.

Shipping information

Explore the research profile

CJC-1295 with DAC5 MG · Single

$51.00

01 / The compound

Understand
the starting point.

Albumin association & GHRH-axis research

02 / Research profile

The pathways.
The possibilities.

What distinguishes the DAC form is the Drug Affinity Complex: a reactive maleimide-containing linker attached to the peptide.

After the peptide enters a biological system, that linker is designed to form a covalent bond with albumin, the most abundant protein in blood. Because albumin itself circulates for a long time, the attached peptide is protected from rapid clearance.

CJC-1295 with DAC is a modified GHRH-related research peptide incorporating a Drug Affinity Complex designed for covalent albumin association. Research on the DAC-containing form has examined albumin binding, receptor activation, peptide persistence and signaling within the GHRH axis in experimental systems.

01 / Research focus

Albumin Bioconjugation

CJC-1295 is built on the first 29 amino acids of growth hormone-releasing hormone, the fragment that carries its biological activity, with amino acid substitutions that improve resistance to enzymatic breakdown. What distinguishes the DAC form is the Drug Affinity Complex: a reactive maleimide-containing linker attached to the peptide. After the peptide enters a biological system, that linker is designed to form a covalent bond with albumin, the most abundant protein in blood. Because albumin itself circulates for a long time, the attached peptide is protected from rapid clearance.

02 / Research focus

Molecular Persistence Research

The DAC modification was developed to investigate how covalent albumin association can alter peptide persistence relative to non-albumin-binding GHRH-related compounds. This research context should be interpreted in terms of molecular design, albumin association and experimental persistence rather than human pharmacokinetic or pharmacodynamic outcomes.

03 / Research focus

GHRH-Axis Research

Research involving CJC-1295 and related GHRH analogues has examined signaling through the GHRH receptor and downstream components of the GH/IGF-1 axis. These pathways provide a model for investigating how structural modifications to GHRH-related peptides can influence receptor signaling and biological persistence under controlled experimental conditions.

Reading the evidence

The cited findings describe the compound in the experimental systems used. Cellular, biochemical and animal results should be interpreted according to their model, methods and endpoints; they do not establish the performance of a GLPZone lot.

03 / Reference data

The details,
in plain sight.

Reference specifications describe a compound. The final lot documentation identifies the material supplied.

CJC-1295 with DAC reference specifications
Compound	CJC-1295 with DAC
Research area	Repair & Recovery
CAS number	863288-34-0
Molecular formula	C165H269N47O46
Molecular weight	3647.18 g/mol
Physical form	Lyophilized
Vial options	5 MG
Intended use	Laboratory research only

Variant amounts are nominal catalog quantities. They are not instructions for use.

04 / Quality & documentation

A number needs
its context.

How testing works

01 / Purity

What is in the sample?

HPLC separates components under a defined method. Read the reported percentage alongside the chromatogram, wavelength, integration method, and scope of the test.

02 / Identity

Is it the expected compound?

Mass spectrometry provides molecular-mass evidence. Identity and chromatographic purity answer different questions; one cannot stand in for the other.

03 / Traceability

Does the report match the vial?

Connect the product name, variant, lot identifier, report date, and issuing laboratory. A report is useful only when its sample can be linked to the material being reviewed.

Independent analysis

Every CJC-1295 with DAC lot is analyzed by Nordicstar Analytical Sciences for identity, content, and purity by HPLC with LC-MS confirmation. Each certificate carries a report number and verification key that can be checked at nordicstarlabs.com/verify. Research references below describe published science, not a certificate for a vial.

Read a COA with confidence

CJC-1295 with DAC lot certificates
Presentation	Lot	HPLC purity	Tested	Certificate
5 MG Current lot	`GLZ-26-CJCDAC-1041`	99.665%	16 Sep 2026	NS-2026-06042
5 MG	`GLZ-26-CJCDAC-759`	99.699%	19 Aug 2026	NS-2026-06155
5 MG	`GLZ-26-CJCDAC-659`	99.592%	06 Jul 2026	NS-2026-06156

05 / Storage & handling

Care for
the material.

Keep sealed lyophilized material cold, dry and protected from light in accordance with the applicable product documentation. Allow a sealed vial to equilibrate before opening to reduce condensation.

The maleimide-containing DAC group is chemically reactive. Thiol-containing buffers or additives can interfere with the intended molecular design; assess their suitability for the experiment.

Use a validated solution-stability protocol appropriate to the formulation. Avoid repeated freeze–thaw cycles.

Explore the handling guide

06 / Common questions

A little more
understanding.

What is the difference between CJC-1295 DAC and CJC-1295 No DAC?

CJC-1295 with DAC contains a Drug Affinity Complex modification designed to extend peptide exposure through albumin binding. No-DAC material does not contain this modification and represents a different research format.

What does "DAC" mean?

DAC stands for Drug Affinity Complex. It is a reactive maleimide-containing linker attached to the peptide designed to form a covalent bond with serum albumin, the most abundant protein in blood, to protect the peptide from rapid clearance.

Is this product the same as Modified GRF (1-29)?

No. Modified GRF (1-29) is commonly referred to as CJC-1295 No DAC. The DAC-containing molecule is structurally distinct because of the albumin-binding linker.

07 / Further reading